Top

Published in:

01-10-2009 | Original Communication

Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon

Authors: Clemence Simonin, M. Tir, D. Devos, A. Kreisler, K. Dujardin, J. Salleron, A. Delval, S. Blond, L. Defebvre, A. Destée, P. Krystkowiak

Published in: Journal of Neurology | Issue 10/2009

Abstract

The purpose of this paper is to describe the effect of 5 years of subthalamic nucleus deep brain stimulation (STN DBS) on levodopa-induced complications, both in everyday life and during an acute challenge with levodopa. Thirty three patients were evaluated during an acute levodopa challenge before surgery and then 1 and 5 years afterwards (both off stim and on stim), using the UPDRS III scale and the CAPSIT-PD scales for dystonia and peak-dose dyskinesia. The UPDRS IV scale was used to assess motor complications in everyday life. The levodopa daily dose and DBS parameters were also recorded. Levodopa-induced complications in everyday life (UPDRS IV) and during an acute levodopa challenge had improved markedly after 1 year (both on and off stim) and still further at 5 years. Peak-dose dyskinesia decreased between the 1- and 5-year measurements. STN DBS decreases levodopa-induced motor complications over the long term. This phenomenon may be explained by (a) overall stabilization of the basal ganglia network and (b) striatal synaptic changes. Our results suggest that DBS leads to both qualitative and quantitative modulations in the corticostriatal loops.

Bejjani BP, Arnulf I, Demeret S, Damier P, Bonnet AM, Houeto JL, Agid Y (2000) Levodopa-induced dyskinesias in Parkinson’s disease: is sensitization reversible? Ann Neurol 47:655–658PubMedCrossRef

Benabid AL, Chabardes S, Seigneuret E (2005) Deep-brain stimulation in Parkinson’s disease: long-term efficacy and safety—what happened this year? Curr Opin Neurol 18:623–630PubMedCrossRef

Brotchie JM, Lee J, Venderova K (2005) Levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm 112:359–391PubMedCrossRef

Ceballos-Baumann AO (2003) Functional imaging in Parkinson’s disease: activation studies with PET, fMRI and SPECT. J Neurol 250(Suppl 1):I15–I23PubMed

Ceballos-Baumann AO, Boecker H, Bartenstein P, von Falkenhayn I, Riescher H, Conrad B, Moringlane JR, Alesch F (1999) A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol 56:997–1003PubMedCrossRef

Cenci MA, Lindgren HS (2007) Advances in understanding l-DOPA-induced dyskinesia. Curr Opin Neurobiol 17:665–671PubMedCrossRef

Defer GL, Widner H, Marie RM, Remy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584PubMedCrossRef

Fraix V, Pollak P, Van Blercom N, Xie J, Krack P, Koudsie A, Benabid AL (2000) Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. Neurology 55:1921–1923PubMed

Gibb WR, Lees AJ (1989) The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 15:27–44PubMedCrossRef

10.

Graybiel AM (2004) Network-level neuroplasticity in cortico-basal ganglia pathways. Parkinsonism Relat Disord 10:293–296PubMedCrossRef

11.

Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS (1998) Altered thalamic response to levodopa in Parkinson’s patients with dopa-induced dyskinesias. Proc Natl Acad Sci USA 95:12016–12021PubMedCrossRef

12.

Herzog J, Pinsker M, Wasner M, Steigerwald F, Wailke S, Deuschl G, Volkmann J (2007) Stimulation of subthalamic fibre tracts reduces dyskinesias in STN-DBS. Mov Disord 22:679–684PubMedCrossRef

13.

Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T, Koulousakis A, Maguire RP, Pruim J, de Jong BM, Herholz K, Sturm V, Heiss WD, Leenders KL (2005) Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 76:1217–1221PubMedCrossRef

14.

Jenkins IH, Fernandez W, Playford ED, Lees AJ, Frackowiak RS, Passingham RE, Brooks DJ (1992) Impaired activation of the supplementary motor area in Parkinson’s disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32:749–757PubMedCrossRef

15.

Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349:1925–1934PubMedCrossRef

16.

Limousin P, Martinez-Torres I (2008) Deep brain stimulation for Parkinson’s disease. Neurotherapeutics 5:309–319PubMedCrossRef

17.

Linazasoro G (2005) New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 26:391–397PubMedCrossRef

18.

Liu Y, Postupna N, Falkenberg J, Anderson ME (2008) High frequency deep brain stimulation: what are the therapeutic mechanisms? Neurosci Biobehav Rev 32:343–351PubMedCrossRef

19.

Piboolnurak P, Lang AE, Lozano AM, Miyasaki JM, Saint-Cyr JA, Poon YY, Hutchison WD, Dostrovsky JO, Moro E (2007) Levodopa response in long-term bilateral subthalamic stimulation for Parkinson’s disease. Mov Disord 22:990–997PubMedCrossRef

20.

Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6:501–506PubMed

21.

Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327–335PubMedCrossRef

22.

Rascol O, Sabatini U, Brefel C, Fabre N, Rai S, Senard JM, Celsis P, Viallard G, Montastruc JL, Chollet F (1998) Cortical motor overactivation in parkinsonian patients with l-dopa-induced peak-dose dyskinesia. Brain 121(Pt 3):527–533PubMedCrossRef

23.

Rektorova I, Sedlackova S, Telecka S, Hlubocky A, Rektor I (2008) Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson’s disease by repetitive transcranial magnetic stimulation. Int J Biomed Imaging 2008:372125PubMedCrossRef

24.

Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123(Pt 11):2297–2305PubMedCrossRef

25.

Schupbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, Czernecki V, Maltete D, Hartmann A, Mallet L, Pidoux B, Dormont D, Navarro S, Cornu P, Mallet A, Agid Y (2005) Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 76:1640–1644PubMedCrossRef

26.

Sestini S, Pupi A, Ammannati F, Silvia R, Sorbi S, Castagnoli A (2007) Are there adaptive changes in the human brain of patients with Parkinson’s disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT. Eur J Nucl Med Mol Imaging 34:1646–1657PubMedCrossRef

27.

Sestini S, Ramat S, Formiconi AR, Ammannati F, Sorbi S, Pupi A (2005) Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson’s disease: a 4-year follow-up study with rCBF SPECT. J Nucl Med 46:1444–1454PubMed

28.

Tir M, Devos D, Blond S, Touzet G, Reyns N, Duhamel A, Waucquier N, Cottencin O, Dujardin K, Debailleul AM, Cassim F, Destee A, Defebvre L, Krystkowiak P (2007) Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of Parkinsonian patients. Neurosurgery 61:297–304PubMedCrossRef

29.

Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V (2001) Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 56:548–551PubMed

30.

Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain 125:575–583PubMedCrossRef

31.

Wider C, Villemure JG, Pollo C, Bogousslavsky J, Burkhard PR, Vingerhoets F (2006) Outcome in 50 consecutive advanced PD patients treated with STN-DBS for 4 to 7 years. Neurology 66:A196

Title: Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon
Authors: Clemence Simonin
M. Tir
D. Devos
A. Kreisler
K. Dujardin
J. Salleron
A. Delval
S. Blond
L. Defebvre
A. Destée
P. Krystkowiak
Publication date: 01-10-2009
Publisher: D. Steinkopff-Verlag
Published in: Journal of Neurology / Issue 10/2009
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-009-5195-2

At a glance: The STEP trials

Springer Medicine

Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2009

Rapid onset frontal leukodystrophy with decreased diffusion coefficient and neuroaxonal spheroids

Successive affection of bilateral temporomesial structures in a case of non-paraneoplastic limbic encephalitis demonstrated by serial MRI and FDG-PET

Communications of the European Neurological Society

Nerve conduction studies in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

Serum uric acid and risk of multiple sclerosis

Sergey Sergeevich Korsakov (1854–1900)